

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BOGATAJ ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003175

FILED: 24 MARCH 2005

U.S. APPLICATION NO: 10/599,289

35 USC §371 DATE:

FOR: GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM
COMPRISING N-(2-(2- PHTHALIMIDOETHOXY)-ACETYL)-L-
ALANYL-D-GLUTAMIC ACID (LK-423)

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/003175, copies are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8752

Date: 9/26/2006



Stephen Auten
Attorney for Applicants
Reg. No. 47,396